Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Recruiting · NCT05900206 · Registry updated 2025-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-09-02 | NCT05900206 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Karolinska University Hospital | 181 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Karolinska University hospital | Stockholm | Sweden | 3 |
| Norrlands University Hospital | Umeå | Sweden | 1 |
| Sankt Gorans Hospital | Stockholm | Sweden | 1 |
| Skåne University Hospital | Malmö | Sweden | 3 |
| Stockholm Southern Hospital | Stockholm | Sweden | 1 |
| Uppsala University Hospital | Uppsala | Sweden | 21 |
| Örebro University Hospital | Örebro | Sweden | 6 |